PA
ARCT icon

Profund Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Profund Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,221
Closed -$108K – 995
2025
Q1 		$108K Sell
10,221
-865
-8% -$13.7K ﹤0.01% 946
2024
Q4 		$188K Sell
11,086
-1,728
-13% -$32.5K 0.01% 1021
2024
Q3 		$297K Sell
12,814
-1,495
-10% -$32K 0.01% 802
2024
Q2 		$348K Sell
14,309
-9,915
-41% -$301K 0.01% 634
2024
Q1 		$818K Buy
24,224
+5,800
+31% +$206K 0.03% 408
2023
Q4 		$581K Sell
18,424
-3,874
-17% -$92.1K 0.03% 472
2023
Q3 		$570K Sell
22,298
-6,310
-22% -$194K 0.03% 430
2023
Q2 		$820K Sell
28,608
-887
-3% -$24.1K 0.04% 368
2023
Q1 		$707K Buy
+29,495
New +$529K 0.04% 397

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Profund Advisors's ARCT Position: Q2 2025 in Review

Profund Advisors sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 10,221 shares — an estimated $108K sold.

Profund Advisors first reported a position in ARCT in Q1 2023 and held it in 9 quarters. The position peaked at $820K in Q2 2023. 144 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Profund Advisors reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Profund Advisors sold 10,221 Arcturus Therapeutics shares in Q2 2025, an estimated $108K.
  • Profund Advisors first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 9 quarters.
  • Profund Advisors's Arcturus Therapeutics position peaked at $820K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Profund Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.